A 3-day Course for CFS/ME
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Feb 4, 2022
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "A 3-day Course for CFS/ME," is looking into a new treatment approach for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), a condition that causes severe fatigue and can significantly affect daily life, work, and social activities. The goal of the trial is to see if a short, three-day course can help improve symptoms and overall well-being for people living with this condition. There is currently a lack of effective treatments for CFS/ME, and finding better options is important not just for patients, but also for society as a whole, given the high costs associated with the condition.
To participate in the trial, individuals should have a CFS/ME diagnosis and be experiencing significant fatigue that keeps them from school or work for at least half of their time. They must also be willing to make changes to improve their health. However, people with certain other health issues, such as serious physical or mental conditions, or who are unable to care for themselves, cannot join. Participants will engage in the 3-day course and complete questionnaires to share their experiences, which will help researchers understand the course's impact. This trial is currently recruiting participants, and successful results could lead to better treatment options and support for those affected by CFS/ME.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • CFS/ME diagnosis based on the Canada Consensus Criteria.
- • At least 50% out of school/work.
- • Readiness to change (corresponding to the preparation phase in transtheoretical model)
- • Has given informed consent.
- Exclusion Criteria:
- * Assessed by a General Practitioner (GP):
- • Underlying physical illness or mental disorder that may explain the symptoms.
- • Suicide risk/previous suicide attempts.
- • Pregnancy.
- • Bedridden and in need of continuous care.
- • Insufficient Norwegian speaking or writing skills to participate in the 3-day course and fill out questionnaires.
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trondheim, , Norway
Patients applied
Trial Officials
Leif Edward Ottesen Kennair, PhD prof
Principal Investigator
NTNU, Department of Psychology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials